多疗法时代慢性肾脏病肾脏保护试验的设计考量
综述指出近5-10年CKD试验显示SGLT2i等药物可延缓肾病进展但不完全阻止,且事件率下降、标准治疗变化等给未来试验设计带来挑战;建议简化设计、扩大纳入、采用平台试验等策略。
要点
- CKD进展存在最终共同通路,宽纳入标准试验可验证多病因疗效与安全性。
- 新药未完全阻止CKD进展或消除心血管风险,仍需新试验。
- 未来试验应简化流程、扩大纳入、采用平台或析因设计。
核心结论
- 多疗法时代CKD试验需应对事件率下降等挑战,应设计足够大、包容且简化的试验。
研究设计与样本
- 综述性文章,总结近5-10年CKD大型高质量试验经验与未来设计考量。
主要发现
- SGLT2i宽纳入标准试验证实对多种CKD病因安全有效,支持CKD进展最终共同通路概念。
- 现有药物联合仍不能完全阻止CKD进展或消除心血管疾病超额风险。
关键数值与推荐
- 原文未报告具体数值标准。
临床怎么用
- 未来试验应简化设计、减少参与负担、扩大纳入既往研究不足人群。
- 可考虑预随机导入期实施标准治疗、析因或平台试验同时评估多种治疗。
局限性
- 本文为设计考量综述,未提供系统检索范围或具体试验数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In the last 5-10 years, several large high-quality research trials testing new treatments versus a dummy treatment in patients with kidney disease have provided new discoveries, particularly among people with diabetes. Some of these trials included patients with a wide variety of kidney diseases and therefore provided important information on how effective the treatment is, and whether it is safe to use for many people (and not just those with a specific type of kidney disease). The findings are particularly important as they suggest that, once established, kidney disease progresses in similar ways regardless of the initiating cause. These new treatments importantly slow kidney disease progression but, even when used together, do not arrest the loss of kidney function. New research is still needed to test new potential treatments. Now that we have several drugs that can be used to treat kidney disease, there are new challenges when designing and conducting new trials. These include the reduced risk of kidney disease progression and heart disease (because of the new treatments available). Future research trials need to include a sufficiently large number of patients to be able to answer research questions reliably. In addition, different types of people and diseases should be included. In an age of increasing regulation and bureaucracy, conducting such trials is challenging. Simplifying the design and conduct of future trials by focusing only on the necessary components needed to answer the research key question(s) is important. Such trials reduce the burden of participation for patients and busy clinical staff, whilst still ensuring careful focus on patient safety and data quality. We hope more high-quality trials that are sufficiently large, inclusive and simple will be conducted in the future, so that kidney teams can offer better care to their patients. ABSTRACT: Nephrology has benefited from conducting increasingly large high-quality trials in the last 5-10 years. In addition to the long-standing known benefits of renin-angiotensin system inhibitors, we now have multiple pharmacotherapies that provide kidney and/or cardiovascular protection for certain types of patient with chronic kidney disease (CKD). These include sodium-glucose co-transporter 2 inhibitors (SGLT2i), a non-steroidal mineralocorticoid receptor antagonist and a glucagon-like peptide-1 receptor agonist. Trials of SGLT2i have had particularly important impact, as wide eligibility criteria in pivotal trials have enabled safety and efficacy across a wide range of causes of CKD to be demonstrated. These findings support the concept of final common pathways of CKD progression and should encourage similar trial designs recruiting broad ranges of patients at risk of CKD progression. This is important as these new drugs do not completely arrest CKD progression nor do they mitigate the full excess of cardiovascular disease. In the current era of multiple therapies to manage risk of CKD progression, trial design and conduct also need to consider new challenges. These include falling event rates, establishing standard of care for participants pre-randomization and improving the inclusion of trial participants understudied in previous trials. Streamlining trial design and conduct and reducing participation burden for patients and clinicians is increasingly important to facilitate larger sample sizes and to optimize adherence to study interventions and follow-up. Potential other solutions include maintaining a focus on wide generalizability (to include understudied patient groups) and empowering patients to volunteer for trials (through public and patient involvement and large-scale invitation methods), as well as innovations in trial design (including use of pre-randomization run-in periods to implement standard of care and factorial or platform trials to assess multiple treatments simultaneously).
引用
- Zhu D, Judge PK, Staplin N, et al. Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease. Nephrol Dial Transplant. 2025. PMID: 39907541. doi:10.1093/ndt/gfae210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。